Filed: 2/12/2026ACC: 0001193125-26-048808
📋 What this filing means
SR ONE CAPITAL MANAGEMENT, LP filed this quarterly 13F‑HR report disclosing 13 equity positions with a total reported market value of $706.38M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
13
Positions
$706.38M
Total AUM (reported)
33.29M
Total Shares
Allocation by class
COMMON STOCK$579.91M82.1%
COMMON SHARES$113.66M16.1%
ORDINARY SHARES$12.80M1.8%
Portfolio Concentration
Top 3$442.84M62.7%
4–10$247.45M35.0%
11–25$16.09M2.3%
Top 3 weight
62.7%
Top 10 weight
97.7%
Voting Authority Distribution
Total shares with voting rights: 33.29M
Sole
Full voting authority
33.29M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole13
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings13
Rows:
Zenas BioPharma, Inc
SOLEShares5.04M
TypeSH
Market value$182.92M
25.90%
Sole
5.04M
Shared
0.00
None
0.00
Arcellx, Inc.
SOLEShares2.35M
TypeSH
Market value$153.00M
21.66%
Sole
2.35M
Shared
0.00
None
0.00
CRISPR Therapeutics AG
SOLEShares2.04M
TypeSH
Market value$106.91M
15.14%
Sole
2.04M
Shared
0.00
None
0.00
Design Therapeutics, Inc.
SOLEShares6.53M
TypeSH
Market value$61.22M
8.67%
Sole
6.53M
Shared
0.00
None
0.00
Mineralys Therapeutics Inc.
SOLEShares1.56M
TypeSH
Market value$56.76M
8.03%
Sole
1.56M
Shared
0.00
None
0.00
ARS Pharmaceuticals, Inc.
SOLEShares4.01M
TypeSH
Market value$46.75M
6.62%
Sole
4.01M
Shared
0.00
None
0.00
ORIC Pharmaceuticals, Inc.
SOLEShares4.51M
TypeSH
Market value$37.75M
5.34%
Sole
4.51M
Shared
0.00
None
0.00
Alumis Inc.
SOLEShares1.96M
TypeSH
Market value$19.13M
2.71%
Sole
1.96M
Shared
0.00
None
0.00
Oruka Therapeutics, Inc
SOLEShares430.33K
TypeSH
Market value$13.04M
1.85%
Sole
430.33K
Shared
0.00
None
0.00
Oculis Holding AG
SOLEShares641.02K
TypeSH
Market value$12.80M
1.81%
Sole
641.02K
Shared
0.00
None
0.00
enGene Holdings Inc.
SOLEShares747.75K
TypeSH
Market value$6.75M
0.96%
Sole
747.75K
Shared
0.00
None
0.00
Nkarta, Inc.
SOLEShares3.33M
TypeSH
Market value$6.17M
0.87%
Sole
3.33M
Shared
0.00
None
0.00
Ultragenyx Pharmaceutical Inc.
SOLEShares137.75K
TypeSH
Market value$3.17M
0.45%
Sole
137.75K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Zenas BioPharma, IncSOLE | Common Stock | 5.04M | SH | $182.92M 25.90% | 5.04M | 0.00 | 0.00 |
Arcellx, Inc.SOLE | Common Stock | 2.35M | SH | $153.00M 21.66% | 2.35M | 0.00 | 0.00 |
CRISPR Therapeutics AGSOLE | Common Shares | 2.04M | SH | $106.91M 15.14% | 2.04M | 0.00 | 0.00 |
Design Therapeutics, Inc.SOLE | Common Stock | 6.53M | SH | $61.22M 8.67% | 6.53M | 0.00 | 0.00 |
Mineralys Therapeutics Inc.SOLE | Common Stock | 1.56M | SH | $56.76M 8.03% | 1.56M | 0.00 | 0.00 |
ARS Pharmaceuticals, Inc.SOLE | Common Stock | 4.01M | SH | $46.75M 6.62% | 4.01M | 0.00 | 0.00 |
ORIC Pharmaceuticals, Inc.SOLE | Common Stock | 4.51M | SH | $37.75M 5.34% | 4.51M | 0.00 | 0.00 |
Alumis Inc.SOLE | Common Stock | 1.96M | SH | $19.13M 2.71% | 1.96M | 0.00 | 0.00 |
Oruka Therapeutics, IncSOLE | Common Stock | 430.33K | SH | $13.04M 1.85% | 430.33K | 0.00 | 0.00 |
Oculis Holding AGSOLE | Ordinary Shares | 641.02K | SH | $12.80M 1.81% | 641.02K | 0.00 | 0.00 |
enGene Holdings Inc.SOLE | Common Shares | 747.75K | SH | $6.75M 0.96% | 747.75K | 0.00 | 0.00 |
Nkarta, Inc.SOLE | Common Stock | 3.33M | SH | $6.17M 0.87% | 3.33M | 0.00 | 0.00 |
Ultragenyx Pharmaceutical Inc.SOLE | Common Stock | 137.75K | SH | $3.17M 0.45% | 137.75K | 0.00 | 0.00 |